Dual-Antigen Bispecifics Reset Relapsed Myeloma

Company Johnson & Johnson (Janssen Research & Development) Event Type Clinical Trial Results (Phase 3, Topline) Modality Bispecific T-Cell Engager Combination (BCMA×CD3 + GPRC5D×CD3) Asset Tecvayli (teclistamab) + Talvey (talquetamab) Target BCMA / GPRC5D Disease Area Relapsed or Refractory Multiple Myeloma Summary Johnson & Johnson…